cyproheptadine has been researched along with Basal Ganglia Diseases in 1 studies
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ABC-C and the Childhood Autism Rating Scale scores improved with cyproheptadine." | 9.11 | Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. ( Akhondzadeh, S; Amini, H; Erfani, S; Gudarzi, SS; Mohammadi, MR; Tehrani-Doost, M; Yasamy, MT, 2004) |
| "The ABC-C and the Childhood Autism Rating Scale scores improved with cyproheptadine." | 5.11 | Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial. ( Akhondzadeh, S; Amini, H; Erfani, S; Gudarzi, SS; Mohammadi, MR; Tehrani-Doost, M; Yasamy, MT, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akhondzadeh, S | 1 |
| Erfani, S | 1 |
| Mohammadi, MR | 1 |
| Tehrani-Doost, M | 1 |
| Amini, H | 1 |
| Gudarzi, SS | 1 |
| Yasamy, MT | 1 |
1 trial available for cyproheptadine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.
Topics: Autistic Disorder; Basal Ganglia Diseases; Child; Child, Preschool; Cyproheptadine; Double-Blind Met | 2004 |